We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis.
- Authors
Sandhu, Mani Ratnesh S.; Chiang, Veronica L.; Tran, Thuy; Yu, James B.; Weiss, Sarah A.; Goldberg, Sarah B.; Aboian, Mariam S.; Kluger, Harriet M.; Mahajan, Amit
- Abstract
Introduction: The study aimed to describe the brain metastases (BM) incidence, at diagnosis and follow-up, in patients initially presenting with stage III or IV melanoma and characterize their metastatic brain lesions. We also sought to describe the association of common genetic mutations and immunotherapy with BM development in advanced melanoma. Methods: Using our institution's tumor registry, we identified patients with initial diagnoses of stage III and stage IV melanoma. In this cohort, we obtained BM incidence at diagnosis and follow-up, characterized the metastatic brain lesions and primary tumor's genetic profile. Results: During the follow-up period, 22.9% of patients with an initial diagnosis of stage III developed BM. In this cohort, the median time for BM occurrence was 20 months; [95% CI (14–29)]. Likewise, 37.7% of patients with Stage IV melanoma presented with BM at the time of diagnosis, and 22.7% of remaining patients developed BM at follow-up over a median duration of 6 months [95% CI (4–11)]. Therefore, suggesting an overall incidence of 51.9% in stage IV melanoma. Next, we observed that the incidence of BM development during the follow-up period significantly decreased from 2012 to 2017 (p < 0.001). Lastly, we found a significantly higher frequency of mutational BRAF in the primary tumor of patients with BM (68.7% vs. 31.2%; p = 0.02). Conclusions: While the overall incidence of BM remains high, the decreasing incidence of BM over the follow-up period is promising. Similar BM incidence in patients with an initial diagnosis of stage III or stage IV warrants appropriate imaging surveillance regimen for stage III patients.
- Subjects
MELANOMA; GENETIC mutation; BRAIN damage; DIAGNOSIS; BRAIN metastasis; RETROSPECTIVE studies
- Publication
Journal of Neuro-Oncology, 2021, Vol 154, Issue 2, p197
- ISSN
0167-594X
- Publication type
Article
- DOI
10.1007/s11060-021-03813-8